Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr1398 Inhibitors

Olr1398 inhibitors are a specialized class of chemical compounds that are specifically designed to target and inhibit the Olr1398 receptor, a member of the olfactory receptor family within the G protein-coupled receptor (GPCR) superfamily. These receptors are crucial components of the olfactory system, which is responsible for detecting and interpreting a vast array of odorant molecules, leading to the perception of distinct smells. Olr1398 inhibitors function by binding to the receptor's active site, where natural odorant molecules would typically bind, or by interacting with allosteric sites that influence the receptor's activity. This binding action prevents the receptor from undergoing the conformational changes necessary to initiate intracellular signaling pathways. By blocking these processes, Olr1398 inhibitors effectively disrupt the receptor's ability to transmit olfactory signals, thereby inhibiting its role in the sensory processing of smells. The design and development of these inhibitors often involve detailed structural studies of the Olr1398 receptor, utilizing advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These studies provide critical insights into the receptor's binding pockets and other structural features, enabling the creation of inhibitors that are highly specific to the Olr1398 receptor and effective in modulating its activity.

Chemically, Olr1398 inhibitors exhibit a diverse range of molecular structures, reflecting the various synthetic strategies used in their design. These compounds can vary from small, lipophilic molecules that easily penetrate cellular membranes to larger, more complex structures that require sophisticated synthetic methods to achieve optimal binding affinity and specificity. The synthesis of Olr1398 inhibitors typically involves multiple steps of organic chemistry, including the construction of molecular frameworks and the incorporation of functional groups that enhance the compound's interaction with the receptor. Once synthesized, these inhibitors undergo rigorous characterization using a variety of analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These methods are employed to ensure the structural integrity, purity, and inhibitory potency of the compounds. The study of Olr1398 inhibitors is important for advancing our understanding of the specific mechanisms by which this olfactory receptor functions and how its activity can be modulated by small molecules. Additionally, this research contributes to the broader field of GPCR modulation, offering valuable insights into the molecular processes underlying sensory perception, particularly within the context of olfaction. By deepening our knowledge of how olfactory receptors operate and how they can be selectively targeted, scientists can explore new avenues in the study of sensory systems and the complex biochemical pathways that govern them.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Erlotinib Hydrochloride

183319-69-9sc-202154
sc-202154A
10 mg
25 mg
$74.00
$119.00
33
(1)

EGFR inhibitor, may hinder cell signaling in certain cancers by targeting EGFR tyrosine kinase.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Targets VEGF and PDGF receptors, could impact angiogenesis and tumor cell proliferation.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

MEK inhibitor, may disrupt the MAPK/ERK pathway, affecting cell growth in specific cancers.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

Targets EGFR with T790M mutation, potentially inhibiting EGFR-mediated signaling pathways.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

JAK1 and JAK2 inhibitor, could affect cytokine signaling and immune response in myelofibrosis.

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Dual inhibitor of EGFR and HER2, may disrupt signaling pathways in breast cancer.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$205.00
$405.00
9
(1)

Targets BCR-ABL tyrosine kinase, potentially inhibiting cell growth in chronic myeloid leukemia.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, could affect cell signaling and angiogenesis in colorectal cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Inhibits Bruton's tyrosine kinase, might impact cell proliferation in B-cell malignancies.

Palbociclib

571190-30-2sc-507366
50 mg
$315.00
(0)

CDK4/6 inhibitor, may impede cell cycle progression in certain breast cancers.